GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Enterprise Value

China National Accord Medicines (SZSE:000028) Enterprise Value : ¥20,370 Mil (As of May. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, China National Accord Medicines's Enterprise Value is ¥20,370 Mil. China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,689 Mil. Therefore, China National Accord Medicines's EV-to-EBIT ratio for today is 7.57.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, China National Accord Medicines's Enterprise Value is ¥20,370 Mil. China National Accord Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,689 Mil. Therefore, China National Accord Medicines's EV-to-EBITDA ratio for today is 7.57.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, China National Accord Medicines's Enterprise Value is ¥20,370 Mil. China National Accord Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥75,881 Mil. Therefore, China National Accord Medicines's EV-to-Revenue ratio for today is 0.27.


China National Accord Medicines Enterprise Value Historical Data

The historical data trend for China National Accord Medicines's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Enterprise Value Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,470.33 20,245.94 18,029.14 14,901.97 18,279.30

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,027.59 28,384.04 22,675.04 18,279.30 21,499.14

Competitive Comparison of China National Accord Medicines's Enterprise Value

For the Medical Distribution subindustry, China National Accord Medicines's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines's Enterprise Value Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Enterprise Value distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's Enterprise Value falls into.



China National Accord Medicines Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

China National Accord Medicines's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

China National Accord Medicines's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

China National Accord Medicines's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20369.685/2689.142
=7.57

China National Accord Medicines's current Enterprise Value is ¥20,370 Mil.
China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,689 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

China National Accord Medicines's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=20369.685/2689.142
=7.57

China National Accord Medicines's current Enterprise Value is ¥20,370 Mil.
China National Accord Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,689 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

China National Accord Medicines's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=20369.685/75881.148
=0.27

China National Accord Medicines's current Enterprise Value is ¥20,370 Mil.
China National Accord Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥75,881 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines Enterprise Value Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines